NEW YORK, Nov. 19 (GenomeWeb News) - Robert Middlebrook has joined Perlegen Sciences as chief corporate development officer, the company said today.
The position is being created for Middlebook as the company expands its partnerships to in-license drug candidates, according to Brad Margus, Perlegen's CEO.
Middlebrook joins Perlegen from Fidelity Investments, where he held numerous positions over the past 11 years, including most recently, senior vice president. Before joining Fidelity, Middlebrook was vice president and principal at Regent Capital, and was at Alpha Industries, a defense electronics firm, for four years.
David Martin has been appointed CEO of GangaGen, a San Francisco biotech company that focuses on bacteriphage preparations for bacterial disease prevention and treatment, the company said today.
Martin comes to GangaGen from Eos Biotechnology, where he was co-founder andCEO until the company was acquired by Protein Design Labs in April. Before founding Eos in 1997, Martin was president of Chiron Therapeutics. Prior to joining Chiron in 1994, Martin was executive vice president of R&D at DuPont, and before joining DuPont in 1990, was the first vice president of R&D at GenenTech, from 1983 to 1990. For 13 years, he was also professor of medicine and biochemistry at the University of California San Francisco.
James Chamberlain has been appointed chairman of the board of directors at Marligen Biosciences, the Ijamsville, Md., company said today. Chamberlain, who currently serves on the board of Xtrana, a Denver biotechnology company, was president of BioSource International from 1989 to 1993, and chairman of the board from 1993 to 2000, when he retired. He has previously served as manager of business development at Amgen, and in executive roles at Amersham and Browning Ferris Industries.
Daniel Chagnovich has been appointed senior scientist in bioinformatics at Velcura Therapeutics , the Ann Arbor, Mich., company said Nov.18.
Chagnovich comes to Velcura, which is developing osteoporosis theapies from Pfizer , where he worked in the molecular technologies group at the Global R&D center in Ann Arbor for two years. At Pfizer, Chagnovich provided bioinformatics support for the company's proteomics and cardiovascular research efforts and developed bioinformatics tools, Velcura said.
Tom Metcalfe has been appointed the head of the new Roche Biomarker Program, the company said Nov. 18. This biomarker program developed out of the of company's joint program in applied genomics, which brought together genomics with the company's pharmaceutical and diagnostics divisions. But unlike the program in applied genomics, the company said, it also incorporates proteomics and metabalomics.
Metcalfe will report to Lee Babiss , the company's vice president for preclinical research and development. Metcalfe is currently the head of business development and operational excellence at Roche Molecular Diagnostics, and will continue in his new role to be based at the company's diagnostics division in Pleasanton, Calif., the company said.
Alan Nies has been appointed to the board of directors of Lexicon Genetics, the company said Nov. 17.
Nies has served as chairman of the Woodlands, Texas, company's medical advisory board since March. Most recently, he was senior vice president of clinical sciences at Merck. Before joining Merck, Nies was a professor of Medicine and head of the division of clinical pharmacology at the University of Colorado Health Sciences Center.
Donald Hawthorne has been appointed president and CEO of Ardais, the Lexington, Mass., clinical genomics company said Nov. 17. Hawthorne replaces Gregory Phelps, who left to "pursue other opportunities," according to the company.
Hawthorne has most recently been a contract operating partner in the healthcare venture capital area, and was formerly CFO and a partner at Ampersand Ventures, a private equity firm.
Nathan Lakey, president of Orion Genomics of St. Louis, told the St. Louis Post-Dispatch Nov. 16 that the company is looking to expand its scientific advisory board.
The company, Lakey said, is looking for experts in human health. "To grow out of your space (of expertise) to related technology, you have to have people who also see the big picture," the newspaper reported that Lakey said.
Orion already has a few distinguished scientists on its SAB: DNA pioneer James Watson, Elaine Mardis from Washington University's Genome Sequencing Center, Richard Myers from Stanford; Michael Finney, president of MJ Research, Michael Lovett, professor of genetics at Washington University, Michael Freeling, professor of plant and microbial biology at the University of California, Berkeley, and LaDeana Hiller, a bioinformatics expert at Washington University School of Medicine.
Joe Fanelli has been appointed director of corporate development at Health Discovery, of Waco Texas, the company said Nov. 14.
Fanelli comes to the biomarker discovery company after serving in various marketing sales and business development positions at Structural Bioinformatics, American Bionetics, Cangene, Microgenics, and Quantum Biotechnologies. He previously also worked at Cetus and Beckman Instruments.
Charles River Laboratories has appointed six new members to its scientific advisory board, the company said Nov. 13. These members include Geoffrey Duyk, president and CSO of Exelixis Pharmaceuticals ; Joseph Catino, senior vice president of research at Bayer; William Hancock, chair of bioanalytical chemistry at the Barnett Institute at Northeastern University; Brian Huber, vice president of biology, drug discovery at GlaxoSmithKline; Colin McKerlie, research scientist in integrative biology at The Hospital for Sick Children in Toronto; and Jill Mesirov, chief informatics officer of the Whitehead Institute.